Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40
Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40
Stifel以買入評級啓動對Cullinan Therapeutics的報道，宣佈目標股價爲40美元
Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $40.
Stifel分析師布拉德利·卡尼諾以買入評級啓動了對庫裏南療法（納斯達克股票代碼：CGEM）的報道，並宣佈目標股價爲40美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。